Is CCNU (lomustine) valuable for treatment of cutaneous epitheliotropic lymphoma in dogs? A critically appraised topic

Table 1 Rates of complete remission in dogs with CTCL

	CCNU		Pegylated liposomal doxorubicin		VDC-1101 and prednisone		Masitinib
References	N	CR (N, %)	N	CR (N, %)	N	CR (N, %)	N	CR (N, %)
Morges, 2014 [4]					10	0 (0%)
Risbon, 2006 [2]	46^a	15 (33%)
Williams, 2006 [3]	36	6^b (33%)
Graham, 1999 [6]	5	5^c (100%)
Vail, 1997 [5]			9	3 (33%)
Holtermann, 2016 [7]							10^d	2 (20%)
TOTAL	87	26 (30%)	9	3 (33%)	10	0 (0%)	1-	2 (20%)

Abbreviations: CR complete remission, N number of dogs
^a14 dogs received CCNU monotherapy, 27 also received glucocorticoids that were later either tapered, discontinued or maintained. The co-administration of prednisone was reported not to be significantly associated with the response or its duration. Other concurrent medications included PEG L-asparaginase (6 dogs), essential fatty acids (8), nonsteroidal anti-inflammatory drugs (3), retinoids (2), and interferon (1)
^b67% of the dogs experiencing a CR also received concurrent glucocorticoids
^c2 dogs may have received concurrent surgery
^dthe response was assessed on the three most dominant “target” lesions

ISSN: 1746-6148